Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) CFO Lawrence A. Kenyon acquired 5,000 shares of the firm's stock in a transaction on Thursday, September 26th. The shares were bought at an average cost of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the acquisition, the chief financial officer now directly owns 5,946 shares of the company's stock, valued at approximately $33,832.74. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Outlook Therapeutics Price Performance
Shares of OTLK opened at $5.34 on Tuesday. The company has a market capitalization of $126.34 million, a P/E ratio of -0.47 and a beta of 0.64. Outlook Therapeutics, Inc. has a one year low of $4.34 and a one year high of $18.00. The business's 50 day simple moving average is $7.17 and its 200-day simple moving average is $7.75.
Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.23. On average, sell-side analysts anticipate that Outlook Therapeutics, Inc. will post -3.59 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Urgent: This election is rigged
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
A number of research firms have weighed in on OTLK. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Thursday, August 15th. Chardan Capital reaffirmed a "buy" rating and set a $53.00 price objective on shares of Outlook Therapeutics in a report on Friday, August 16th. Finally, Ascendiant Capital Markets decreased their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $48.20.
Get Our Latest Report on OTLK
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Great Point Partners LLC boosted its position in Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock valued at $12,557,000 after buying an additional 221,510 shares during the last quarter. AQR Capital Management LLC bought a new position in Outlook Therapeutics in the 2nd quarter valued at $75,000. Squarepoint Ops LLC bought a new position in Outlook Therapeutics in the 2nd quarter valued at $232,000. Susquehanna Fundamental Investments LLC bought a new position in Outlook Therapeutics in the 2nd quarter valued at $303,000. Finally, LVW Advisors LLC bought a new position in Outlook Therapeutics in the 2nd quarter valued at $352,000. 11.20% of the stock is currently owned by institutional investors.
Outlook Therapeutics Company Profile
(
Get Free Report)
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
